Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This trial plans to enroll patients with stage III-IVA (AJCC 8th, except T3N0-1 or T4N0)
locoregionally-advanced nasopharyngeal carcinoma (LANPC). Patients will be randomized in a
1:1 ratio to receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and
concurrent cisplatin-radiation or the same regimen plus Sintilimab. All patients will receive
intensity-modulated radiotherapy (IMRT). Sintilimab will begin on day 1 of induction
chemotherapy and continue every 3 weeks for 12 cycles.